← FDA DRUG APPROVALS

FDA ANDA · ANDA077457

OCTREOTIDE

octreotide acetate

Sponsor: FRESENIUS KABI USA

APPLICATION
ANDA077457
TYPE
ANDA
ORIGINAL APPROVAL
2006-02-10
LATEST ACTION
2024-09-25
ROUTE
INTRAVENOUS, SUBCUTANEOUS, INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Prescription

Products

OCTREOTIDE ACETATE (PRESERVATIVE FREE)Prescription
OCTREOTIDE ACETATE EQ 0.5MG BASE/ML · INJECTABLE · INJECTION
OCTREOTIDE ACETATE (PRESERVATIVE FREE)Prescription
OCTREOTIDE ACETATE EQ 0.05MG BASE/ML · INJECTABLE · INJECTION
OCTREOTIDE ACETATE (PRESERVATIVE FREE)Prescription
OCTREOTIDE ACETATE EQ 0.1MG BASE/ML · INJECTABLE · INJECTION

Approval history

2024-09-25Labeling · Supplement 24 · standardAP
2024-09-25Labeling · Supplement 21 · standardAP
2023-06-30Labeling · Supplement 16 · standardAP
2023-06-30Labeling · Supplement 19 · standardAP
2023-06-30Labeling · Supplement 15 · standardAP
2023-06-30Labeling · Supplement 11 · standardAP
2018-03-09Labeling · Supplement 6 · standardAP
2018-03-09Labeling · Supplement 7 · standardAP
2012-11-30Labeling · Supplement 5 · standardAP
2006-02-10OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →